Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart extension study in Atopic Dermatitis
NCT04893707Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Jun 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04893707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893707.